TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03003286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstuck and on Target (UOT)
Description: Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Teachers Supporting Students (PATSS)
Description: The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
Study: NCT05657210

Intervention type: GENETIC
Intervention: Mutation
Study: NCT04217135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evidence-based medications vs. high-dose hydralazine + evidence-based medications
Description: randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
Study: NCT05657210

Intervention type: GENETIC
Intervention: Mutation

Intervention type: GENETIC
Intervention: Mutation
Study: NCT04514718

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser
Description: low energy holmium laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser
Description: low energy holmium laser
Study: NCT01141803

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apples
Description: 550g of apples/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple pomace
Description: 22g apple pomace/day
Study: NCT03385031

Intervention type: OTHER
Intervention: CBCT imaging
Description: CBCT imaging at first and last fraction of radiotherapy treatment

Intervention type: OTHER
Intervention: CBCT imaging
Description: CBCT imaging at first and last fraction of radiotherapy treatment

Intervention type: OTHER
Intervention: CBCT imaging
Description: CBCT imaging at first and last fraction of radiotherapy treatment
Study: NCT03232398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Oral Tablet [Eliquis]
Description: Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Oral Tablet [Eliquis]
Description: Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
Study: NCT03221868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: An exercise-based program following a 12-week periodization using mostly circuit-like activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
Study: NCT01672463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN-007
Description: Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.
Study: NCT00666588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT
Study: NCT03232398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
Study: NCT00666588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT
Study: NCT02766296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Emotional Working Memory Training
Description: This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Working Memory Training
Description: This training utilized a fixed dual 1-back training paradigm.
Study: NCT00666588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT01235936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Different dose levels
Study: NCT04661306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi (Sleep Healthy Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
Study: NCT00666588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01937494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histamine-benzylic alcohol (magistral preparation)
Description: passive exposure to histamine during a bronchial hyperresponsiveness challenge
Study: NCT04070963

Intervention type: OTHER
Intervention: HbA1C
Description: To take additional blood test of HbA1C once patient consented to the study
Study: NCT00562614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-2101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SLx-2101
Study: NCT03809949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Opioid anesthesia
Description: To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nonopioid anesthesia
Description: To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
Study: NCT03282045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysobact Complete Sprey
Description: Inhaling spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tantum Verde® Spray
Description: Inhaling spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngal® Oromucosal Spray
Description: Inhaling spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaling spray
Study: NCT03805243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for somnonaute device
Description: test of sensors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for uronaute device
Description: test of sensors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for toconaute device
Description: test of sensors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for neuronaute device
Description: test of sensors
Study: NCT00666588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03968653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Debio 0123 will be given as an oral capsule for 3 days during each 21-day cycle, except Cycle 1 which is of 24 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 2 onwards in Group A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Debio 0123 will be given as an oral capsule for 3 or 6 days during each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Debio 0123 will be given as an oral capsule for 3 or 6 days during each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given as an IV infusion in combination with Debio 0123 on Day 1 from Cycle 1 onwards.
Study: NCT03805243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for cardioskin device
Description: test of sensors
Study: NCT02061124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer 1600 mg TID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer 1600 mg TID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1600 mg TID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1600 mg TID for 7 days
Study: NCT02711332

Intervention type: OTHER
Intervention: capillary blood sampling
Description: Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.

Intervention type: OTHER
Intervention: venous blood sampling
Description: Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
Study: NCT00949364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles).
Study: NCT01602185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (drug used like antitussive)
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine (drug used in Alzheimer's disease)
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (lactose)
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Study: NCT04251923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retro pubic sling
Description: patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
Study: NCT03068988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: without mesenchymal stem cells
Description: rotator cuff surgery without mesenchymal stem cells
Study: NCT03927196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: extended counseling
Description: Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
Study: NCT03805672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Enoxaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Enoxaparin
Study: NCT02093169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Lu AF35700
Description: One 30 mg single dose for one day; orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Lu AF35700
Description: Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
Study: NCT02630966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab 300 mg IV infusion
Study: NCT04525664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 MG Oral Tablet
Description: 20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
Study: NCT00903695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memory XL
Description: An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT01549860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST Therapy
Description: Non-contact low frequency ultrasound therapy
Study: NCT03025503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nipple stimulation
Study: NCT02028624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
Study: NCT02332278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early feeding
Description: Fluid diet four hours after cesarean section
Study: NCT02630966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab 300 mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride IV infusion
Study: NCT03677466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive strategy
Description: Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
Study: NCT02924194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation ON
Description: The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation OFF
Description: The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor.
Study: NCT02946567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noisy City information about hearing health care
Description: Participants will play the game Noisy City, which contains information about hearing health care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic Game
Description: Participants will play a generic game without any particular information about hearing health care.
Study: NCT03466099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD001 Injection
Description: Intravitreal KVD001 Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD001 Injection
Description: Intravitreal KVD001 Injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham Procedure
Study: NCT01975662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
Study: NCT01671293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent remote care model
Description: A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
Study: NCT00385944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
Study: NCT03082183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: once daily
Study: NCT02332278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late feeding
Description: Fluid diet 12 hours after cesarean section